Literature DB >> 4818273

Active specific immunotherapy of minimal residual tumor: excision plus neuraminidase-treated tumor cells.

A Rios, R L Simmons.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4818273     DOI: 10.1002/ijc.2910130109

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


× No keyword cloud information.
  7 in total

1.  Melphalan-mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor.

Authors:  R C Bocian; S Ben-Efraim; S Dray; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

2.  Tumor therapy of neoplastic diseases with tumor cells and neuraminidase. Further experimental studies on chessboard vaccination in canine mammary tumors.

Authors:  H H Sedlacek; G Hagmayer; F R Seiler
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Inhibition of pulmonary metastases of B16 melanoma with irradiated tumor cells and BCG.

Authors:  J Tai; A Guclu; T Ghose; S Norvell
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

Review 4.  Chemical xenogenization of experimental tumors.

Authors:  P Puccetti; L Romani; M C Fioretti
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

5.  Tumor immunity. An overview.

Authors:  B V Siegel
Journal:  Am J Pathol       Date:  1978-11       Impact factor: 4.307

6.  Neuraminidase and tumor immunotherapy.

Authors:  H H Sedlacek; F R Seiler; H G Schwick
Journal:  Klin Wochenschr       Date:  1977-03-01

7.  Melphalan-induced enhancement of tumor cell immunostimulatory capacity as a mechanism for the appearance of potent antitumor immunity in the spleen of mice bearing a large metastatic MOPC-315 tumor.

Authors:  R C Bocian; S Dray; S Ben-Efraim; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.